Customers
Measured outcomes, not marketing claims.
Every Sterira deployment starts by naming the number it has to move: a reject rate, a cycle time, a deviation count. Here is how sterile fill-finish teams put autonomy to work and what they got back.
Case · biologics CDMO
Recovering yield lost to false rejects.
A biologics CDMO was scrapping good units of a high-value mAb to over-cautious inspection. After deploying the inspect-and-release agent on one line, false rejects fell 61% with no increase in escapes.
- Single-line pilot on the worst offender.
- Payback inside one quarter on recovered yield.
- Expanded to three more lines within two quarters.
Case · vaccine manufacturer
Freeing the lyophilizer bottleneck.
Lyophilizers gated the whole site's output. The lyo-and-cycle agent cut cycle time 27% by tracking the collapse margin live, recovering capacity that would otherwise have required a capital project.
- No change to cake quality or potency.
- QbD design-space evidence generated for filing.
- Capacity recovered without new equipment.
Case · injectables site
Eliminating intervention deviations.
Gowned interventions drove the site's deviation count. Robotic handling plus live contamination control cut aseptic-intervention deviations 4.5× and kept the isolator sealed across campaigns.
- Routine handling moved to robotics.
- Live risk model under Annex 1.
- Deviation investigations down sharply.
In their words
What teams tell us.
"The false-reject line item dropped by more than half. That recovered yield paid for the deployment in a quarter."
Sterile injectables site
"Recovering a quarter of the lyo cycle without touching cake quality is capacity we couldn't buy any other way."
Vaccine manufacturer
Land and expand
One line becomes a fleet.
Because value is proven on a hard metric before expansion, adoption compounds: the same customers add agents, lines, and sites. That is what drives 129% net revenue retention across the base.
See how deployment scales →Who we work with
Across the sterile landscape.
Biologics & mAb makers
High-value fills where precision and yield dominate.
Vaccine manufacturers
Lyophilized products constrained by cycle time.
Sterile injectable sites
High-volume aseptic lines with deviation pressure.
CDMOs
Multi-program operations competing on RFT and speed.
"We treat Sterira as the operating system for the suite now. Every new line comes online already autonomous."
Global biopharma
FAQ
Common questions.
Under NDA, yes. Sterile manufacturing is confidential by nature, so public logos are limited, but we arrange direct reference conversations during evaluation.
Against a single agreed hard metric (reject rate, cycle time, deviation count, or release time), baselined before the pilot and measured on real batches.
Read-only connection takes weeks; measurable outcomes typically land within the first pilot campaign, with payback often inside a quarter on high-value product.
Put a number on your own line.
We'll baseline your metric and show you the achievable delta.